申请人:SmithKline Beecham plc
公开号:US06265408B1
公开(公告)日:2001-07-24
Sulphonamide compounds according to formula (I) or pharmaceutically acceptable salts thereof:
wherein:
Ar is naphthyl, phenyl or thienyl optionally substituted by one or more substituents selected from the group consisting of C1-6 alkyl optionally substituted by NR7R8, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkylthio, cyano, nitro, halogen, CF3, C2F5, NR7R8, CONR7R8, NR7COR8, S(O)pNR7R8, CHO, OCF3, SCF3, COR9, CH2OR9, CO2R9 or OR9 where p is 1 or 2 and R7, R8 and R9 are independently hydrogen or C1-6 alkyl.
R1 and R2 are independently hydrogen or C1-6alkyl or together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring optionally substituted by Cl-6alkyl and optionally containing a further heteroatom selected from nitrogen, sulphur or oxygen, the nitrogen atom being substituted by hydrogen, C1-6 alkyl or cycloC3-7alkyl;
R3 is hydrogen or C1-6 alkyl;
X is oxygen, sulphur or a bond;
n is 2 or 3; and
m is 1 or 2;
are provided.
The present compounds are useful in the treatment of CNS disorders.
化合物式(I)的磺胺化合物或其药学上可接受的盐:
其中:Ar是萘基,苯基或噻吩基,可选择地被来自C1-6烷基,其上可选地被NR7R8取代,C2-6烯基,C2-6炔基,C1-6烷基硫,氰基,硝基,卤素,CF3,C2F5,NR7R8,CONR7R8,NR7COR8,S(O)pNR7R8,CHO,OCF3,SCF3,COR9,CH2OR9,CO2R9或OR9的一个或多个取代基选自的取代基取代。
其中p为1或2,R7,R8和R9独立地为氢或C1-6烷基。
R1和R2独立地为氢或C1-6烷基,或与它们连接的氮原子一起形成一个5-至7-成员杂环环,可选择地被Cl-6烷基取代,并可选择地含有来自氮,硫或氧的进一步杂原子,该氮原子被氢,C1-6烷基或环C3-7烷基取代;
R3为氢或C1-6烷基;
X为氧,硫或键;
n为2或3;和
m为1或2。
提供了目前化合物在治疗中枢神经系统疾病方面的用途。